Toll Receptors in Atherosclerosis
动脉粥样硬化中的 Toll 受体
基本信息
- 批准号:7213932
- 负责人:
- 金额:$ 46.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-09 至 2012-01-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAllelesAnimalsAtherosclerosisBlood VesselsBone MarrowCD14 geneCD36 geneCellsChronicCommunicable DiseasesDendritic CellsDietDiseaseDisease ProgressionDisease regressionDoctor of PhilosophyEndothelial CellsEnvironmentFatty acid glycerol estersFibroblastsGene DeletionGenesGenetic ProgrammingHMGB1 ProteinHumanHyaluronic AcidHyperlipidemiaImmuneImmune systemIn VitroInfectionInfectious AgentInfiltrationInflammationInflammation MediatorsInflammatoryInflammatory ResponseLesionLigandsLinkLipidsLipoproteinsLow Density Lipoprotein ReceptorLymphocyteMediatingModelingMusNatural Killer CellsPlayPreventionProcessPublishingReceptor ActivationReportingResearch PersonnelRiskRisk FactorsRoleSeverity of illnessSignal TransductionSmooth Muscle MyocytesSterilityTLR1 geneTLR2 geneTLR4 geneTLR6 geneTestingTherapeutic InterventionThinkingTimeToll-Like Receptor 1Toll-like receptorsWound Healingbiglycandisorder riskfeedingin vivolipoteichoic acidmacrophagemacrophage stimulatory lipopeptide 2monocyteoxidized lipidpathogenreceptorresearch studyresponsesensor
项目摘要
DESCRIPTION (provided by applicant): Atherosclerosis is not just a simple lipid storage disease. It is now appreciated that atherosclerosis is also a chronic inflammatory disease of the arterial wall. This has been established by studies of specific inflammatory gene deletions in hyperlipidemic mice that influence disease severity. The Toll-like receptors (TLR) of the innate immune system, which sense pathogens and mediate cell activation, can provide an important link between infection, inflammation and atherosclerosis. We discovered that TLR2-mediated inflammation influences disease progression in low density lipoprotein receptor-deficient (LDLr-/-) mice. Proatherogenic inflammatory TLR2-mediated responses to unknown endogenous agonists are mediated by non bone marrow-derived cells including endothelial cells, smooth muscle cells and adventitial fibroblasts. In contrast the proatherogenic inflammatory responses to the known exogenous, synthetic TLR2 agonist, Pam3, are mediated at least in part by bone marrow-derived cells including macrophages. We will confirm our hypothesis that TLR2-mediated cell activation by either endogenous or exogenous TLR2 agonists is predominately proatherogenic and analyze how TLR2-mediated inflammation influences atherosclerosis. In Aim 1 we will study endogenous agonists of TLR2. We will characterize region-specific expression of TLR2 in vivo in non-bone marrow-derived cells and document the time course of the effect of TLR2 on macrophage infiltration into lesions. We will identify candidate endogenous proatherogenic agonists and define the role of the TLR2 co-receptors, TLR1, TLR6, CD14 and and CD36, in TLR2 signaling. In Aim 2 we will study exogenous agonists of TLR2. We will determine if macrophages are sufficient for mediating proatherogenic inflammation induced by defined exogenous agonists. We will define the role of the TLR2 co-receptors with known exogenous agonists and finally, we will examine if TLR2-mediated signaling participates in disease regression. These studies will enhance our understanding of inflammatory responses in atherosclerosis and potentially identify new TLR targets for therapeutic intervention to reverse or reduce disease risk.
描述(由申请人提供):动脉粥样硬化不仅仅是一种简单的脂质储存疾病。现在认识到动脉粥样硬化也是动脉壁的慢性炎症性疾病。这一点已经通过对高脂血症小鼠中影响疾病严重程度的特异性炎症基因缺失的研究得到了证实。先天免疫系统的Toll样受体(TLR)可以感知病原体并介导细胞活化,可以在感染、炎症和动脉粥样硬化之间提供重要联系。我们发现TLR 2介导的炎症影响低密度脂蛋白受体缺陷(LDLr-/-)小鼠的疾病进展。致动脉粥样硬化炎性TLR 2介导的对未知内源性激动剂的反应由非骨髓来源的细胞介导,包括内皮细胞、平滑肌细胞和外膜成纤维细胞。相反,对已知的外源性合成TLR 2激动剂Pam 3的致动脉粥样硬化性炎症反应至少部分地由骨髓来源的细胞(包括巨噬细胞)介导。我们将证实我们的假设,即内源性或外源性TLR 2激动剂介导的TLR 2细胞活化主要是促动脉粥样硬化的,并分析TLR 2介导的炎症如何影响动脉粥样硬化。在目标1中,我们将研究TLR 2的内源性激动剂。我们将在非骨髓来源的细胞中表征TLR 2在体内的区域特异性表达,并记录TLR 2对巨噬细胞浸润到病变中的作用的时间过程。我们将确定候选的内源性促动脉粥样硬化激动剂,并确定TLR 2共受体,TLR 1,TLR 6,CD 14和CD 36,在TLR 2信号转导中的作用。在目标2中,我们将研究TLR 2的外源性激动剂。我们将确定巨噬细胞是否足以介导由确定的外源性激动剂诱导的致动脉粥样硬化性炎症。我们将确定TLR 2共受体与已知外源性激动剂的作用,最后,我们将检查TLR 2介导的信号传导是否参与疾病消退。这些研究将增强我们对动脉粥样硬化炎症反应的理解,并有可能确定新的TLR靶点,用于治疗干预以逆转或降低疾病风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linda K Curtiss其他文献
Linda K Curtiss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linda K Curtiss', 18)}}的其他基金
Macrophage Produced Phospholipid Transfer Protein (PLTP)
巨噬细胞产生磷脂转移蛋白 (PLTP)
- 批准号:
8257889 - 财政年份:2011
- 资助金额:
$ 46.6万 - 项目类别:
Macrophage Produced Phospholipid Transfer Protein (PLTP)
巨噬细胞产生磷脂转移蛋白 (PLTP)
- 批准号:
8111498 - 财政年份:2011
- 资助金额:
$ 46.6万 - 项目类别:
Role of Toll-Like Receptors in Atherogenesis
Toll 样受体在动脉粥样硬化形成中的作用
- 批准号:
7456192 - 财政年份:2008
- 资助金额:
$ 46.6万 - 项目类别:
IMMUNOCHEMICAL STRUCTURE FUNCTION OF APOLIPOPROTEIN A-I
载脂蛋白A-I的免疫化学结构功能
- 批准号:
6389119 - 财政年份:1990
- 资助金额:
$ 46.6万 - 项目类别:
IMMUNOCHEMICAL STRUCTURE/FUNCTION OF APOLIPOPROTEIN AI
载脂蛋白 AI 的免疫化学结构/功能
- 批准号:
2702190 - 财政年份:1990
- 资助金额:
$ 46.6万 - 项目类别:
IMMUNOCHEMICAL STRUCTURE/FUNCTION OF APOLIPOPROTEIN A-I
载脂蛋白 A-I 的免疫化学结构/功能
- 批准号:
3362582 - 财政年份:1990
- 资助金额:
$ 46.6万 - 项目类别:
IMMUNOCHEMICAL STRUCTURE FUNCTION OF APOLIPOPROTEIN A-I
载脂蛋白A-I的免疫化学结构功能
- 批准号:
6536965 - 财政年份:1990
- 资助金额:
$ 46.6万 - 项目类别:
Immunochemical Structure/Function of Apolipoprotein A-I
载脂蛋白 A-I 的免疫化学结构/功能
- 批准号:
7258356 - 财政年份:1990
- 资助金额:
$ 46.6万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 46.6万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 46.6万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 46.6万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 46.6万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 46.6万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 46.6万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 46.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 46.6万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 46.6万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 46.6万 - 项目类别: